2023Biotechnology Industry Innovation Forum
5month25On2023The Biotechnology Industry Innovation Forum and the New Product Release Conference of Zhongshan Bio's Sterile Sodium Hyaluronate was successfully held at the Beijing National Convention Center. The forum was themed 'New Forces in Sterility, Leading the New Future', and focused on exchanges and discussions on policy regulations, R&D innovation, and industry trends in fields such as biotechnology, bio-manufacturing, and biomedicine. At the same time, Frost & SullivanFrost & SullivanFrost & Sullivan, in collaboration with Zhongshan Biology, jointly released the 'China Aseptic Grade Hyaluronic Acid White Paper' (hereinafter referred to as the 'Report'). Yang Lizhu, the consulting director for Frost & Sullivan Greater China, was invited to attend the event and provided an in-depth interpretation of the report at the press conference.
The 'White Paper on Chinese Aseptic-grade Hyaluronic Acid' (hereinafter referred to as the 'Report') was jointly released by Frost & Sullivan and Zhongshan Biotechnology. The report delves into four major chapters: the hyaluronic acid raw material industry, Chinese aseptic-grade hyaluronic acid raw materials, end-use applications of aseptic-grade hyaluronic acid, and the market competition landscape of aseptic-grade hyaluronic acid raw materials. It aims to interpret the current development status and prospects of the aseptic-grade hyaluronic acid industry from a scientific, rational, and professional analytical perspective.
Frost & Sullivan Greater China Consulting Director Yang Lizhu
Yang Lizhu pointed out that China is the world's largest producer and seller of hyaluronic acid raw materials, with its fermentation technology level, production volume, and quality all reaching international advanced standards.
According to the research data from Frost & Sullivan,2022The total sales volume of hyaluronic acid raw materials in China accounted for82.7%Chinese enterprises rank at the top of global sales volumes, while overseas enterprises account for a smaller proportion of hyaluronic acid raw material sales. COVID-19 pandemicIt has had a short-term impact on both the supply and demand sides of the global hyaluronic acid raw material market. However, encouraged by policies in China's import and export trade market, the sales volume of China's hyaluronic acid raw material market in the past5Maintains continuous growth annually, from2017year26.5RMB 10 billion, an increase of2022year39.0RMB 10 billion, with an annual compound growth rate of8.0%.
Looking at hyaluronic acid raw materials from different grades,2022The sales volume of cosmetic-grade hyaluronic acid raw materials accounted for the highest proportion, followed by pharmaceutical-grade raw materials.3.6%However, the export price of pharmaceutical-grade hyaluronic acid raw materials in China is about2,700 - 25,000US dollar/kilograms, for other levels it is approximately150 - 500US dollar/kilograms. Due to the high cost, pharmaceutical-grade raw materials have a significant profit margin advantage.
The report shows that due to China2021The policy dividend released at the beginning of the year regarding food-grade hyaluronic acid has led to a rapid short-term growth in sales of food-grade hyaluronic acid raw materials. It is expected that over the next five years, the Chinese hyaluronic acid raw material market will maintain8.4%The high compound growth rate, in2027Annual achievement58.2RMB 10 billion.
Source: Analysis by Frost & Sullivan
Yang Lizhu then briefly introduced the aseptic-grade hyaluronic acid raw material and its advantages. Sterile-grade sodium hyaluronate raw materials will become the preferred choice for customers producing sterile preparations and sterile medical devices using non-final sterilization processes.
Sterile grade hyaluronic acid raw materials refer to non-final sterilized hyaluronic acid raw material products produced through aseptic manufacturing processes. The process design for non-final sterilized products uses aseptic filtration to remove bacteria, ensuring product quality through strict aseptic control. Sodium hyaluronate is sensitive to high temperatures and decomposes significantly under moist heat sterilization conditions, causing significant fluctuations in product viscosity before and after sterilization, resulting in products that do not meet quality standard requirements. For manufacturers of sterile preparations and sterile medical devices that cannot be finally sterilized, using sterile raw materials eliminates the risk of viscosity degradation during material sterilization, avoiding experimental costs and time costs.
Currently, the market for sterile-grade sodium hyaluronate raw materials is still in its infancy, with no mature or large-scale sterile production lines in place, and there is still a distance to go before mass production and sales can be achieved. Since the end-use applications of sterile-grade hyaluronic acid raw materials are similar to those of pharmaceutical-grade hyaluronic acid raw materials, the market scale of pharmaceutical-grade hyaluronic acid raw materials can be used to predict the downstream demand for sterile-grade raw materials.
Pharmaceutical-grade hyaluronic acid raw materials are generally used in drug treatment or medical aesthetics. Due to the special nature of their use, the overall performance requirements for products are high, and they need to beNMPAAuthentication is required for use, so the price is also higher. The report shows,2022The market scale of pharmaceutical-grade hyaluronic acid raw materials in China in21.6tons2017 - 2022Annual compound growth rate11.6%expected2022 - 2027Annual compound growth rate11.4%, achieved37.1tons. Similarly, the downstream applications of sterile-grade hyaluronic acid raw materials are mainly in the pharmaceutical field. Due to their higher product quality requirements, production process requirements, and qualification standards, the expected selling price will be higher than that of pharmaceutical-grade raw materials. In the future, it is expected that sterile-grade hyaluronic acid raw materials will replace a portion of the market share for pharmaceutical-grade hyaluronic acid raw materials.
Due to the special properties of cross-linked hyaluronic acid, such as good biocompatibility, longer degradation time in vivo, and effective filling and shaping effects, it has become the mainstream soft tissue filling material and is gradually replacing other fillers such as collagen. It is widely used in various plastic surgery fields.
Yang Lizhu said, With the continuous improvement of domestic enterprises' technology and craftsmanship levels, local hyaluronic acid companies in the medical beauty sector are increasingly competing with foreign brands both domestically and even in the international market, leading to a gradual increase in the sales volume of domestic hyaluronic acid fillers for medical beauty applications.
Compared to surgical plastic surgery, non-surgical minimally invasive medical aesthetics represented by injections have a faster recovery time, lower costs and risks, thus enjoying a higher market acceptance and repeat purchase rate.2022In [year], the market scale of hyaluronic acid end-products for medical aesthetics in China was larger than that of other medical end-application areas, reaching77.7RMB 10 billion,2017 - 2022Annual compound growth rate19.9%, and is expected to be24.9%The compound growth rate is at2027Annual achievement236.6RMB 10 billion.
Source: Analysis by Frost & Sullivan
In addition, In the field of orthopedics, hyaluronic acid can be used for the treatment of bone and joint diseases, fracture fixation, joint stiffness, and injections for lumbar discectomy. It is estimated that the market scale of hyaluronic acid end-products for orthopedic treatment in China will be2027reaching about18.4Yuan, with a compound annual growth rate of6.0%In the field of ophthalmology, hyaluronic acid end-products include hyaluronic acid adhesives used in ophthalmic surgeries (cataract surgery, intraocular lens implantation, penetrating keratoplasty, glaucoma surgery, removal of intraocular foreign bodies, ocular trauma surgery, etc.) and hyaluronic acid artificial tears for treating symptoms such as dry eye syndrome. In the future, it is expected that the overall market size of hyaluronic acid products for ophthalmic treatment in China will further expand, estimated2027reaching about52RMB 10 billion.
The report shows that Zhongshan Biotechnology is the first company in China to launch sterile-grade sodium hyaluronate raw materials produced by aseptic production lines. Zhongshan Biotechnology's sterile-grade sodium hyaluronate raw materials meet the terminal application standards of the downstream pharmaceutical industry. The Eighth Workshop of Zhongshan Biotechnology is an automated workshop specializing in the production of sterile hyaluronic acid raw materials and is also the first sterile sodium hyaluronate workshop in China. The equipment in this workshop is selected and used with production equipment from first-class domestic and international enterprises. From the source of material transfer, full-process airtight operation is adopted, and the production line is fully automated, meeting the production standards for sterile-grade sodium hyaluronate raw materials. Compared with traditional pharmaceutical-grade raw material production workshops, Zhongshan Biotechnology's sterile production workshop has stricter quality control, with higher requirements for production equipment, process technology, and production environment.
Based on research into China's sterile-grade hyaluronic acid industry, Frost & Sullivan has confirmed that Shandong Zhongshan Biotechnology Co., Ltd. is the pioneer of sterile-grade sodium hyaluronate. At this forum, Yang Lizhu presented a market position confirmation certificate to Shandong Zhongshan Biotechnology Co., Ltd.
Yang Lizhu, consulting director of Frost & Sullivan Greater China region (left), presented the certificate to Cui Hu, founder of Zhongshan Biosciences (right).
Recommended Reading
